Clinical trials: Diastolic Murmurs
Hypertension
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
To evaluate the safety and efficacy, in particular with regard to renal function of telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to endstage renal impairment after 12 weeks of treatment
- Trial name
- ESPRIT (NCT02178306)
- Testing
- Telmisartan low dose, Telmisartan high dose
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Congestive Heart Failure
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
This is a study to evaluate the response of patients with hypertension and early stage heart failure to valsartan.
- Trial name
- NCT00241098
- Testing
- valsartan
- Volunteers
- 37 people
- Sponsor
- Novartis
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Cardiac Disease
MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram
Clinical validation study of the MyoVista wavECG.
- Trial name
- NCT04804969
- Testing
- MyoVista wavECG Test
- Where
- 5 sites in United States
- Volunteers
- 575 people
- Sponsor
- Heart Test Laboratories, Inc.
Hypertension
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension
The purpose of this study is to determine the safety and efficacy of azilsartan, once daily (QD), in subjects with essential hypertension.
- Trial name
- NCT00759551
- Testing
- Azilsartan, Olmesartan
- Volunteers
- 555 people
- Sponsor
- Takeda
Heart Failure; With Decompensation, Cardiorenal Syndrome
The Aortix CRS Pilot Study
The Aortix CRS Pilot Study: An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome
- Conditions
- Heart Failure; With Decompensation, Cardiorenal Syndrome, Cardio-Renal Syndrome, Heart Failure
- Trial name
- NCT04145635
- Testing
- Aortix System
- Where
- 19 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Procyrion
Essential Hypertension
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT06465264
- Testing
- Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2
- Where
- China
- Volunteers
- 499 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis
Diastolic Heart Failure
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure and an Left Ventricular…
- Trial name
- NCT00303498
- Testing
- Sitexsentin sodium
- Where
- 52 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Pfizer
AI-driven, Self-directed Blood Pressure Monitoring
imPulse™ Tor System Self-Directed Cuffless Blood Pressure Monitoring
Self-measured, non-invasive accurate blood pressure monitoring continues to be a major challenge for automated vital sign measurement systems.
- Trial name
- NCT05386654
- Testing
- imPulse™ Tor System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Level 42 AI, Inc.
Heart Rate, Blood Pressure
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
This study will evaluate the safety of phenylephrine hydrochloride 10 mg + acetaminophen 500 mg + dimethindene maleate 1 mg compared to phenylephrine hydrocloride 10 mg alone in healthy volunteers.
- Conditions
- Heart Rate, Blood Pressure, Arrhythmias
- Trial name
- NCT01026961
- Testing
- Phenylephrine HCL, Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
- Where
- Brazil
- Sponsor
- Novartis
Hypertension
A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to amlodipine monotherapy in patients with non-essential hypertension, not controlled on amlodipine alone.
- Trial name
- NCT00171366
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 1,422 people
- Sponsor
- Novartis
Diastolic Heart Failure
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.
- Trial name
- BREAK-DHF-I (NCT00662116)
- Testing
- alagebrium
- Where
- 30 sites in United States
- Volunteers
- 160 people
- Sponsor
- Synvista Therapeutics, Inc
Cardiac Output and Preload Assessment, Lung Water Assessment
Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess Thermodilution Cardiac Output, Global End Diastolic Volume and Extravascular Lung Water
The primary objective of this study is to obtain the TPTD, GEDV and EVLW measurements from existing indwelling femoral arterial Volume View™ catheter and central venous catheters.
- Trial name
- NCT01405040
- Where
- 4 sites in Germany, Switzerland
- Volunteers
- 97 people
- Sponsor
- Edwards Lifesciences
Stage 2 Diastolic Hypertension
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP>= 100 mmHg).
- Trial name
- NCT01218100
- Testing
- nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 664 people
- Sponsor
- Forest Laboratories
Essential Hypertension
Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly
To assess the efficacy of individually optimized doses of olmesartan medoxomil compared to losartan in elderly and very elderly patients with essential hypertension.
- Trial name
- NCT00751751
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary, losartan + hydrochlorothiazide, if necessary
- Where
- Germany
- Volunteers
- 441 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hypertension
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects (superiority of FDC over monotherapies).
- Trial name
- NCT01977794
- Testing
- Bisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals